IL-1 inhibitors appeared more effective than tocilizumab. Among the five patients who started the anti-IL-6 product, only two met the primary endpoint of sustained event-free remission. Three ...

Bristol–Myers Squibb (BMS) has entered a potential ∼US$1 billion agreement with Alder ... for the development of second-generation IL-6 inhibitors or fast follow-ups by other pharmaceutical ...

and IL-1. 1 Early-generation p38 inhibitors (for example, BIRB796 and SCIO469) showed only moderate success owing to their poor specificity and dose-dependent toxicity. More recently, new ...

The 24-week results showed persistence or improvement in the icotrokinra group and rapid improvement in patients switched ...

Apogee's strong financial position, with $731.1 million in cash, funds operations through Q1 2028, de-risking its ambitious ...